Opendata, web and dolomites

CylcoRu4PACT TERMINATED

Cyclometallated ruthenium complexes for photo-activated chemotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CylcoRu4PACT project word cloud

Explore the words cloud of the CylcoRu4PACT project. It provides you a very rough idea of what is the project "CylcoRu4PACT" about.

model    photoreactivity    penetrates    compounds    hindering    efficacy    sterically    synthesized    treatments    complexes    oxygen    dark    absorption    maximizing    modifies    optimally    quenches    grounds    phototherapy    concentrations    containing    prodrugs    curing    lines    tumour    tissues    ligand    place    hard    chemotherapy    shift    released    wavelength    wavelengths    vitro    biological    clinic    hypoxic    usually    photochemotherapeutic    photosubstitution    ruthenium    visible    red    concentration    introduce    photochemical    sensitive    human    synthesize    excited    bond    cyclometallated    reactions    chemotherapeutic    alternative    limit    recover    measured    occurring    irradiation    groups    overcome    too    cytotoxicity    stand    carbon    energy    fails    patient    consist    therapy    toxicity    cyclometallation    polypyridyl    minimizing    metal    treatment    cell    determined    efficient    keeping    window    photodynamic    light    tumours    anticancer    compound    locally    cancer   

Project "CylcoRu4PACT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.universiteitleiden.nl/en/staffmembers/sylvestre-bonnet
 Total cost 165˙598 €
 EC max contribution 165˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 165˙598.00

Map

 Project objective

Chemotherapy is efficient in curing cancer, but most treatments are very hard to stand for the patient, and side effects limit treatment efficacy. Phototherapy is a promising alternative, where the toxicity of a light-sensitive chemotherapeutic compound is locally released upon visible light irradiation of the compound-containing tumour. Photodynamic therapy is already available in the clinic for oxygen-rich tumours; however, it fails when the oxygen concentration at the place of irradiation is too low. In this project I propose to synthesize new ruthenium-based photochemotherapeutic compounds containing cyclometallated ligand, and to test them in an in vitro model of hypoxic cancer. The presence of a carbon-metal bond is known to shift the light absorption properties of ruthenium polypyridyl complexes towards the photodynamic window, a wavelength range where light penetrates optimally into biological tissues. However, cyclometallation usually quenches the ligand photosubstitution properties of ruthenium compounds because it strongly modifies the energy of their excited states. In this project, I will introduce sterically hindering groups on the cyclometallated ligand to recover photoreactivity of the complexes while keeping light absorption at high wavelengths. The challenges of this project consist on the one hand in achieving efficient ligand photosubstitution reactions with cyclometallated ruthenium compounds, and on the other hand in minimizing the cytotoxicity in the dark while maximizing cytotoxicity after red light irradiation at low oxygen concentrations. The ruthenium prodrugs will be synthesized, their photochemical properties will be measured, and their cytotoxicity against human cancer cell lines will be determined in an in vitro model of hypoxic cancer. This project will set new grounds in the treatment of hypoxic tumours and propose a new way to overcome side effects occurring in traditional anticancer chemotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYLCORU4PACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYLCORU4PACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More